Figure 4.

PI3K inhibitors cell signalling modification in melanoma cell lines bearing RAC1 and BRAF mutations. Melanoma cell lines with different genotypes were grown under standard conditions. Cells were treated with vehicle (control) or 100 nM of the indicated PI3K inhibitors for 24 h. Lysates were analysed by Western blot for PAK, AKT, and ERK phosphorylation. Representative data of 3 independent experiments are shown